GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » EV-to-Revenue

OliX Pharmaceuticals (XKRX:226950) EV-to-Revenue : 125.33 (As of Jul. 13, 2025)


View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, OliX Pharmaceuticals's enterprise value is ₩737,584 Mil. OliX Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₩5,885 Mil. Therefore, OliX Pharmaceuticals's EV-to-Revenue for today is 125.33.

The historical rank and industry rank for OliX Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

XKRX:226950' s EV-to-Revenue Range Over the Past 10 Years
Min: 9.79   Med: 133.53   Max: 5804.74
Current: 125.33

During the past 11 years, the highest EV-to-Revenue of OliX Pharmaceuticals was 5804.74. The lowest was 9.79. And the median was 133.53.

XKRX:226950's EV-to-Revenue is ranked worse than
86.59% of 992 companies
in the Biotechnology industry
Industry Median: 8.155 vs XKRX:226950: 125.33

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-13), OliX Pharmaceuticals's stock price is ₩39000.00. OliX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩347.75. Therefore, OliX Pharmaceuticals's PS Ratio for today is 112.15.


OliX Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for OliX Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals EV-to-Revenue Chart

OliX Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.67 149.66 28.19 14.53 67.45

OliX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.63 9.48 20.16 67.45 131.69

Competitive Comparison of OliX Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, OliX Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OliX Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's EV-to-Revenue falls into.


;
;

OliX Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

OliX Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=737584.338/5885.315
=125.33

OliX Pharmaceuticals's current Enterprise Value is ₩737,584 Mil.
OliX Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,885 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OliX Pharmaceuticals  (XKRX:226950) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

OliX Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=39000.00/347.752
=112.15

OliX Pharmaceuticals's share price for today is ₩39000.00.
OliX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩347.75.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OliX Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of OliX Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OliX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines